{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-013664","form_type":"8-K","ticker":"PLX","cik":"0001006281","company_name":"Protalix BioTherapeutics, Inc.","filed_at":"2024-10-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.333219+00:00","generated_at":"2026-05-30T09:55:45.564612+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Protalix to present Phase I PRX-115 data in late-breaking poster at ACR Convergence 2024","bullets":["PRX-115 is a recombinant PEGylated uricase for uncontrolled gout treatment.","Data from Phase I trial will be presented at ACR Convergence 2024 (Nov 14-19, Washington, D.C.).","Poster session: Monday Nov 18, 10:30 AM-12:30 PM EST; abstract number L05.","Abstract available on ACR abstracts website; poster to be posted on Protalix website.","No clinical results disclosed; presentation details only."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-013664","json":"https://secwatch.observer/filing/0001558370-24-013664.json","markdown":"https://secwatch.observer/filing/0001558370-24-013664.md","text":"https://secwatch.observer/filing/0001558370-24-013664.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006281/000155837024013664/0001558370-24-013664-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006281/000155837024013664/plx-20241025x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T09:55:45.564612+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}